Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(4-Oxo–5,6 ,7 ,8-tetrahydro–[1.3]-thiazolo[5.4-c]-azepin–2–yl)-acetamide is a small molecule compound with the molecular formula C9H11N3O2S and a molecular weight of approximately 225.27 g/mol.[2][3][4][5] It belongs to the class of organic compounds known as n-acetylarylamines (a type of acetamides). The compound has been referenced in chemical databases such as DrugBank (DB08776), PubChem (CID:739358), and ChemSpider (ID:646276). It is considered an experimental molecule and there are no approved therapeutic indications or marketed products containing this substance.[2][3][5] No detailed mechanism of action or biological target has been established in public sources; it is primarily used for research purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(4-oxo-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-2-yl)acetamide.